Subcutaneous injection of a cyclic peptide antagonist of vitronectin receptor-type integrins inhibits retinal neovascularization.
Flynn
J T
JT
Cousins
S
S
D000818:Animals; D004305:Dose-Response Relationship, Drug; D000860:Hypoxia / Q000150:complications; D007279:Injections, Subcutaneous; D016023:Integrins / Q000037:antagonists & inhibitors*; D051379:Mice; D010456:Peptides, Cyclic / Q000008:administration & dosage*; D019030:Receptors, Vitronectin / Q000037:antagonists & inhibitors*; D015861:Retinal Neovascularization / Q000209:etiology / Q000517:prevention & control*
D016023:Integrins; D010456:Peptides, Cyclic; D019030:Receptors, Vitronectin